-
signatures indicative of treatment sensitivity, uncovering and mitigating paths to drug resistance, and predicting toxicity effects of drugs in healthy cells. In the dynamic research environment at SciLifeLab
-
and data interpretation for patient stratification, discovery of biomarkers for disease risk, diagnosis, drug response and health monitoring. Research in precision medicine is expected to use existing
-
interpretation for patient stratification, discovery of biomarkers for disease risks, diagnosis, drug response and monitoring of health. The precision medicine research is expected to make use of existing strong
-
, and data interpretation for patient stratification, discovery of biomarkers for disease risks, diagnosis, drug response and monitoring of health. The precision medicine research is expected to make use
-
medicine and diagnostics covers data integration, analysis, visualization, and data interpretation for patient stratification, discovery of biomarkers for disease risks, diagnosis, drug response and
-
, discovery of biomarkers for disease risks, diagnosis, drug response and monitoring of health. The precision medicine research is expected to make use of existing strong assets in Sweden and abroad, such as